Eli Lilly and (LLY)
Eli Lilly and (LLY) Stock Price, Analysis & Data
| Bid | 1180.5 |
| Market Cap | 1.05T |
| Revenue (ttm) | 79.67B |
| Net Income (ttm) | 26.71B |
| Beta | 0.51 |
| EPS (ttm) | 29.74 |
| PE Ratio (ttm) | 40.65 |
| Forward PE | 24.93 |
| P/B (ttm) | 33.80 |
| P/S (ttm) | 13.20 |
| Earnings Date | Oct 29, 2026 |
| Ask | 1182.46 |
| Volume | 2,115,056 |
| Avg. Volume (20D) | 3,002,886 |
| Open | 1194.01 |
| Previous Close | 1207.27 |
| Day's Range | 1171.20 - 1199.00 |
| 52-Week Range | 685.15 - 1249.45 |
| Analyst | Buy |
| Price Target | 1344 (13.88%) |
| Dividends | $6.92 (0.57%) |
| Ex-Dividend Date | Aug 14, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabe...
Financial Performance
In 2025, Eli Lilly and's revenue was 65.18B, an increase of 44.7% compared to the previous year's 45.04B. Earnings were 20.64B, an increase of 94.9%.
Financial StatementsAnalyst Forecast
According to 27 analyst ratings, the average rating for LLY stock is "Buy". The 12-month stock price forecast is 1344, which is upside of 13.88% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
11 hours ago · Simply Wall St.
Eli Lilly (LLY) Steps Up Legal Fight Over Illegal Retatrutide SalesEli Lilly (NYSE: LLY) has intensified legal action against U.S. entities accused of selling unauthorized versions of its experimental obesity drug retatrutide. The company is pursuing multiple lawsuit...